Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Not yet recruiting 5Recruiting 4Active not recruiting 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Carcinoma, Transitional Cell 1Advanced Breast Cancer 1

Interventions

Specimen Handling 302Magnetic Resonance Spectroscopy 261pembrolizumab 249Carboplatin 184Cyclophosphamide 175Biopsy 167Cisplatin 157Gemcitabine 134Paclitaxel 130Bevacizumab 123fludarabine 115Nivolumab 108Radiotherapy 107Oxaliplatin 88Docetaxel 87Fluorouracil 85Capecitabine 83venetoclax 78Dexamethasone 76Pemetrexed 72Rituximab 69Leucovorin 69Drug Therapy 69atezolizumab 67durvalumab 66Radiosurgery 65Blood Specimen Collection 64Doxorubicin 63Standard of Care 62Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × disitamab vedotin × 90 days × Clear all
NCT05831878 2026-05-13

RC48-ADC in HER2-low Advanced Breast Cancer

RenJi Hospital

Phase NA Recruiting
36 enrolled
Breast

Advanced Breast Cancer

NCT06157892 2026-05-05

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Seagen Inc.

Phase 2 Recruiting
172 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04879329 2026-04-21

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Seagen Inc.

Phase 2 Recruiting
372 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06966453 2026-04-21

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Pfizer

Phase 1/2 Recruiting
100 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡